Chairman Cathal Friel said: "We are delighted to enter 2021 with another contract signed by the Venn team in Breda with this top-three global pharmaceutical client"
() said a top-three global pharmaceuticals company has renewed its contract with the group's Venn Life Sciences division until the end of the year.
The team in the Breda office, in the Netherlands, will provide chemistry, manufacturing and control consultancy (CMC) services to one of the client's vaccine development programmes.
In a statement, Open Orhan chairman Cathal Friel said: "We are delighted to enter 2021 with another contract signed by the Venn team in Breda with this top-three global pharmaceutical client.
“Venn have been providing CMC support to this top tier company since 2012 and are pleased to be continuing to work with this client in their vaccine development programme.”
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE